Breast Cancer Drugs Market by Types (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors, and Aromatase Inhibitors), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global breast cancer drugs market size is anticipated to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of diseases coupled with emerging novel therapies.
For effective management of breast cancer the early detection is a key factor. Early detection of disease gives desired outcomes such as increasing number of treatment options, raising survival rate, and improves quality of life. Based on an article 2018 Research Fast Facts was published by Susan G. Komen, stated that regular screening and early detection reduces the death rate by 30%.
Based on International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, in women, breast cancer is fifth major cause responsible for deaths, which is around 626,989 deaths each year. As per the American Cancer Society, in 2018, around 266,000 new cases were diagnosed in women in U.S. Moreover, aging is one of the highest risk factors. As per Cancer Treatment Centers of America, breast cancer in women above 60 years of age are possibly diagnosed and only around 10-12% of cases were found in women less than 45 years of age.
Huge presence of disease along with expiry of patent are key factors responsible for increasing investment in R&D of novel products. The R&D expenditure from companies such as Merck & Co. Inc., Pfizer, Sanofi, Johnson & Johnson Services Inc., AbbVie Inc., GlaxoSmithKline plc., and Celgene Corporation are rising significantly, but sudden fall is noted for AstraZeneca, Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd, Novartis Company.
Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of disease is major factor responsible for propelling the market growth over the forecast period.
- Increasing concern for effective treatment and management, and rising investment of key players in research and innovation are anticipated to drive the market growth.
- Growing number of pipelined drugs and rising research and development of novel drugs are projected to fuel the growth of the market.
- Environmental factors, new generation treatments and bio-similar versions, changing lifestyle, physical inactivity, and hormonal changes are some factors responsible for driving the market expansion.
- Rising new treatment methods and therapies is expected to boost the market growth over the forecast period.
- Stringent regulations, expiry of the patented drugs, and prolonged therapies degrading the health are anticipated to hamper the market growth.
- Lack of accessibility of medical attention and less awareness about healthcare among people are projected to impede the market expansion.
Scope of the Report
The report on the global breast cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Breast Cancer Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Types (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors, and Aromatase Inhibitors) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc. |
Market Segment Insights
HER2 inhibitors segment is projected to hold a major market share
Based on types, the breast cancer drugs market is segmented into hormonal receptors, mitotic inhibitors, HER2 inhibitors, anti-metabolites, CDK 4/6 inhibitors, and aromatase inhibitors. The HER2 inhibitors segment is expected to hold a key share of the market during the forecast period owing to rising incidence of HER2 positive breast cancer. As per article published in 2013, by F. Hoffman La Roche Ltd., one out of five women were diagnosed the breast tumor would have HER2 positive cancer. In addition, demand is rapidly increasing from emerging countries such as Asia Pacific and Latin America which is projected to propel the segment growth over the forecast period.
However, the CDK 4/6 inhibitor segment is anticipated to expand at a rapid pace during the forecast period. These drugs are anticipated to increase the patient’s survival rate having metastatic breast cancer.
North America is anticipated to dominate the market
On the basis of regions, the breast cancer drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to rising awareness among people and increasing presence of established R&D infrastructure. Furthermore, presence of major market players such as Merck & Co., Inc.; AbbVie, Inc.; Pfizer, Inc.; and Celgene Corporation in the region is projected to boost the regional market growth.
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. Globally, demand of drugs is increasing which results in growing manufacturing and R&D facilities by manufacturers in this region. Initiatives taken by several organizations to educate people, raise funds, and create awareness about disease is expected to fuel the regional market growth.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Breast Cancer Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Breast Cancer Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Breast Cancer Drugs Market - Supply Chain
4.5. Global Breast Cancer Drugs Market Forecast
4.5.1. Breast Cancer Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Breast Cancer Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Breast Cancer Drugs Market Absolute $ Opportunity
5. Global Breast Cancer Drugs Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Breast Cancer Drugs Market Size and Volume Forecast by Types
5.3.1. Hormonal Receptors
5.3.2. Mitotic Inhibitors
5.3.3. HER2 Inhibitors
5.3.4. Anti-metabolites
5.3.5. CDK 4/6 Inhibitors
5.3.6. Aromatase Inhibitors
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Breast Cancer Drugs Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Breast Cancer Drugs Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Breast Cancer Drugs Demand Share Forecast, 2019-2026
7. North America Breast Cancer Drugs Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Breast Cancer Drugs Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Breast Cancer Drugs Market Size and Volume Forecast by Types
7.4.1. Hormonal Receptors
7.4.2. Mitotic Inhibitors
7.4.3. HER2 Inhibitors
7.4.4. Anti-metabolites
7.4.5. CDK 4/6 Inhibitors
7.4.6. Aromatase Inhibitors
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Breast Cancer Drugs Demand Share Forecast, 2019-2026
8. Latin America Breast Cancer Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Breast Cancer Drugs Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Breast Cancer Drugs Market Size and Volume Forecast by Types
8.4.1. Hormonal Receptors
8.4.2. Mitotic Inhibitors
8.4.3. HER2 Inhibitors
8.4.4. Anti-metabolites
8.4.5. CDK 4/6 Inhibitors
8.4.6. Aromatase Inhibitors
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Breast Cancer Drugs Demand Share Forecast, 2019-2026
9. Europe Breast Cancer Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Breast Cancer Drugs Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Breast Cancer Drugs Market Size and Volume Forecast by Types
9.4.1. Hormonal Receptors
9.4.2. Mitotic Inhibitors
9.4.3. HER2 Inhibitors
9.4.4. Anti-metabolites
9.4.5. CDK 4/6 Inhibitors
9.4.6. Aromatase Inhibitors
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Breast Cancer Drugs Demand Share Forecast, 2019-2026
10. Asia Pacific Breast Cancer Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Breast Cancer Drugs Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Breast Cancer Drugs Market Size and Volume Forecast by Types
10.4.1. Hormonal Receptors
10.4.2. Mitotic Inhibitors
10.4.3. HER2 Inhibitors
10.4.4. Anti-metabolites
10.4.5. CDK 4/6 Inhibitors
10.4.6. Aromatase Inhibitors
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Breast Cancer Drugs Demand Share Forecast, 2019-2026
11. Middle East & Africa Breast Cancer Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Breast Cancer Drugs Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Breast Cancer Drugs Market Size and Volume Forecast by Types
11.4.1. Hormonal Receptors
11.4.2. Mitotic Inhibitors
11.4.3. HER2 Inhibitors
11.4.4. Anti-metabolites
11.4.5. CDK 4/6 Inhibitors
11.4.6. Aromatase Inhibitors
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Breast Cancer Drugs Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Breast Cancer Drugs Market: Market Share Analysis
12.2. Breast Cancer Drugs Distributors and Customers
12.3. Breast Cancer Drugs Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. F. Hoffmann-La Roche Ltd.
12.4.2. Novartis AG
12.4.3. AbbVie, Inc.
12.4.4. AstraZeneca
12.4.5. Eli Lilly and Company
12.4.6. Celgene Corporation
12.4.7. Biocon
12.4.8. Merck & Co., Inc.
12.4.9. Genzyme Corporation
12.4.10. Janssen Global services LLC
Segments Covered in the Report
The global breast cancer drugs market has been segmented on the basis of
Types
- Hormonal Receptors
- Mitotic Inhibitors
- HER2 Inhibitors
- Anti-metabolites
- CDK 4/6 Inhibitors
- Aromatase Inhibitors
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- AbbVie, Inc.
- AstraZeneca
- Eli Lilly and Company
- Celgene Corporation
- Biocon
- Merck & Co., Inc.
- Genzyme Corporation
- Janssen Global services LLC
- MacroGenics, Inc.
- Celldex Therapeutics
- Onyx Pharmaceuticals Inc.
- BioNumerik Pharmaceuticals, Inc.
Key players competing in the breast cancer drugs market are F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.
Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, in March 2017, Kisqali was approved by the Food and Drug Administration (FDA) for HR+/HER2 which was the first-line treatment for metastatic breast cancer along with an aromatase inhibitor.
Our Clients
Related Reports
Some other reports from this category!
